When should statin (HMG-CoA reductase inhibitor) therapy be initiated in a patient with hyperlipidemia and what are the contraindications for statin initiation?

When to Start Statin Therapy

Initiate statin therapy immediately in all adults with established atherosclerotic cardiovascular disease (ASCVD) using high-intensity statins, regardless of baseline LDL-C levels, and for primary prevention based on a risk-stratified approach that considers age, diabetes status, LDL-C levels, and calculated 10-year ASCVD risk. 1, 2, 3

Secondary Prevention (Established ASCVD)

Start high-intensity statin therapy immediately for all patients with clinical ASCVD, regardless of age or baseline cholesterol levels. 2, 4, 3

• This includes patients with history of myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, peripheral arterial disease, carotid artery disease, or prior coronary revascularization 3
• High-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) reduce LDL-C by ≥50% 4
• For very high-risk ASCVD patients with LDL-C ≥70 mg/dL on maximally tolerated statin, add ezetimibe; if still ≥70 mg/dL, consider adding PCSK9 inhibitor 2, 4

Primary Prevention: Risk-Stratified Approach

Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)

Initiate maximally tolerated statin therapy, preferably high-intensity, without calculating 10-year ASCVD risk. 2, 4, 3

• This applies to adults aged 20-75 years 3
• No risk calculation needed—treat based on LDL-C level alone 4

Diabetes Mellitus (Ages 40-75 Years)

Start at least moderate-intensity statin therapy for all patients with diabetes and LDL-C ≥70 mg/dL, without calculating 10-year ASCVD risk. 2, 4, 3

• Escalate to high-intensity statin for patients with multiple ASCVD risk factors or those aged 50-75 years 4
• For type 2 diabetes with established ASCVD or chronic kidney disease, target LDL-C <70 mg/dL with high-intensity statin 2

High 10-Year ASCVD Risk (≥20%)

Initiate high-intensity statin therapy to reduce LDL-C by ≥50% in adults aged 40-75 years with calculated 10-year ASCVD risk ≥20%. 1, 4, 3

Intermediate 10-Year ASCVD Risk (7.5% to <20%)

Initiate moderate-to-high intensity statin therapy to reduce LDL-C by ≥30% in adults aged 40-75 years with 10-year ASCVD risk of 7.5% to <20%, particularly when risk-enhancing factors are present. 1, 4

Risk-enhancing factors that favor statin initiation include: 1

• Family history of premature ASCVD
• Persistently elevated LDL-C ≥160 mg/dL
• Metabolic syndrome
• Chronic kidney disease
• History of preeclampsia or premature menopause (age <40 years)
• Chronic inflammatory disorders (rheumatoid arthritis, psoriasis, chronic HIV)
• South Asian ancestry
• Persistent triglycerides ≥175 mg/dL
• Apolipoprotein B ≥130 mg/dL
• High-sensitivity C-reactive protein ≥2.0 mg/L
• Ankle-brachial index <0.9
• Lipoprotein(a) ≥50 mg/dL or 125 nmol/L

Borderline Risk (5% to <7.5%) and Low Risk (<5%)

For adults with 10-year ASCVD risk of 5% to <7.5%, risk-enhancing factors may favor statin therapy; for those with risk <5%, statins are generally not indicated unless LDL-C ≥190 mg/dL. 1

Using Coronary Artery Calcium (CAC) Score for Uncertain Cases

When the decision about statin therapy remains uncertain in intermediate-risk adults (7.5% to <20%), measure CAC score to refine risk assessment. 1, 4

• CAC score = 0: Reasonable to withhold statin therapy and reassess in 5-10 years, except in smokers, patients with diabetes, or strong family history of premature ASCVD 1, 4
• CAC score 1-99: Favors statin therapy, especially in those ≥55 years 1
• CAC score ≥100 or ≥75th percentile: Statin therapy indicated 1, 4

Special Populations

Adults >75 Years

Continue statin therapy in patients >75 years with established ASCVD if already prescribed. 2, 4

• For primary prevention in adults >75 years without established ASCVD, consider moderate-intensity statin after discussing potential benefits and risks 4
• Consider stopping statin when functional decline, multimorbidity, frailty, or reduced life expectancy limits potential benefits 4
• The evidence for initiating statins in adults ≥76 years for primary prevention is insufficient 5

Chronic Kidney Disease

Initiate statin or statin/ezetimibe combination in patients with CKD, except for those on dialysis without established ASCVD. 2, 3

Pediatric Patients (≥10 Years)

For children ≥10 years with heterozygous familial hypercholesterolemia, start with atorvastatin 10 mg daily (range 10-20 mg). 6

• For homozygous familial hypercholesterolemia, start with 10-20 mg daily (range 10-80 mg) 6

---

Contraindications to Statin Initiation

Absolute Contraindications

Do not initiate statins in patients with acute liver failure, decompensated cirrhosis, or hypersensitivity to statins. 6

• Active hepatic disease or unexplained persistent elevations of serum transaminases are contraindications 6
• Pregnancy and breastfeeding are absolute contraindications—stop statins 1-2 months before contemplating pregnancy 3

Clinical Situations Where Statins Should Not Be Used

Avoid statins in heart failure without other indications for statin use, aortic stenosis without coronary artery disease and no other indications, and dialysis-dependent CKD without established ASCVD. 2

Conditions Requiring Caution or Temporary Discontinuation

Temporarily discontinue statins in patients experiencing acute or serious conditions at high risk of developing renal failure secondary to rhabdomyolysis. 6

Risk factors for myopathy and rhabdomyolysis include: 6

• Age ≥65 years
• Uncontrolled hypothyroidism
• Renal impairment
• Concomitant use with certain drugs (fibrates, cyclosporine, HIV protease inhibitors, clarithromycin, itraconazole, nefazodone)
• Higher statin dosages

Discontinue statins immediately if markedly elevated creatine kinase levels occur or if myopathy or immune-mediated necrotizing myopathy (IMNM) is diagnosed or suspected. 6

---

Monitoring After Initiation

Obtain lipid profile at baseline, 4-12 weeks after statin initiation or dose change, and every 3-12 months thereafter. 1, 2, 4

• Monitor for adverse effects including liver enzymes and muscle symptoms 2
• Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever 6
• If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue statins 6

---

Common Pitfalls to Avoid

Do not use low-dose or low-intensity statins when moderate- or high-intensity is indicated, as this leaves patients undertreated. 4

Do not withhold statins in very high-risk patients based solely on concerns about age or baseline cholesterol levels—the benefit clearly exceeds potential adverse effects in established ASCVD. 3, 7

Do not fail to assess adherence—many patients discontinue statins prematurely; only 29.8% of patients without persistent statin therapy had tried at least 2 different statins. 8